DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES)

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2022 Jun 20

PMID 35723298

Authors

Young Kyung Ko

Hayeon Kim

Yoonseok Lee

Young-Sun Lee

Jeong-An Gim

Affiliations

Soon will be listed here.

Abstract

The role of differentially methylated regions (DMRs) in nonalcoholic fatty liver disease (NAFLD) is unclear. This study aimed to identify the role of DMR in NAFLD development and progression using the Korean Genome and Epidemiology Study (KoGES) cohort. We used laboratory evaluations and Illumina Methylation 450 k DNA methylation microarray data from KoGES. The correlation between fatty liver index (FLI) and genomic CpG sites was analyzed in 322 subjects. Longitudinal changes over 8 years were confirmed in 33 subjects. To identify CpG sites and genes related to FLI, we obtained enrichment terms for 6765 genes. DMRs were identified for both high ( = 128) and low ( = 194) groups on the basis of FLI 30 in 142 men and 180 women. To confirm longitudinal changes in 33 subjects, the ratio of follow-up and baseline investigation values was obtained. Correlations and group comparisons were performed for the 8 year change values. , , and were hypermethylated in the increased FLI groups, whereas and were hypermethylated in the decreased FLI groups. DMRs describing NAFLD were determined, and functions related to inflammation were identified. Factors related to longitudinal changes are suggested, and blood circulation-related functions appear to be important in the management of NAFLD.

Citing Articles

Survival Rate and Chronic Diseases of TCGA Cancer and KoGES Normal Samples by Clustering for DNA Methylation.

Gim J Life (Basel). 2024; 14(6).

PMID: 38929750 PMC: 11204879. DOI: 10.3390/life14060768.

Epigenetic Profiling of Type 2 Diabetes Mellitus: An Epigenome-Wide Association Study of DNA Methylation in the Korean Genome and Epidemiology Study.

Seo H, Park J, Hwang J, Choi H, Park S, Lee J Genes (Basel). 2023; 14(12).

PMID: 38137029 PMC: 10743302. DOI: 10.3390/genes14122207.

A Genomic Information Management System for Maintaining Healthy Genomic States and Application of Genomic Big Data in Clinical Research.

Gim J Int J Mol Sci. 2022; 23(11).

PMID: 35682641 PMC: 9180925. DOI: 10.3390/ijms23115963.

References

Hagstrom H, Thiele M, Roelstraete B, Soderling J, Ludvigsson J . Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. Gut. 2020; 70(1):170-179. DOI: 10.1136/gutjnl-2019-320446. View

Arguello G, Balboa E, Arrese M, Zanlungo S . Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta. 2015; 1852(9):1765-78. DOI: 10.1016/j.bbadis.2015.05.015. View

French S . Epigenetic events in liver cancer resulting from alcoholic liver disease. Alcohol Res. 2013; 35(1):57-67. PMC: 3860418. View

Kim Y, Han B . Cohort Profile: The Korean Genome and Epidemiology Study (KoGES) Consortium. Int J Epidemiol. 2016; 46(2):e20. PMC: 5837648. DOI: 10.1093/ije/dyv316. View

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Sanna C, Rosso C, Marietti M, Bugianesi E . Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016; 17(5). PMC: 4881539. DOI: 10.3390/ijms17050717. View

Harrison S, Bashir M, Guy C, Zhou R, Moylan C, Frias J . Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019; 394(10213):2012-2024. DOI: 10.1016/S0140-6736(19)32517-6. View

Dugue P, Jung C, Joo J, Wang X, Wong E, Makalic E . Smoking and blood DNA methylation: an epigenome-wide association study and assessment of reversibility. Epigenetics. 2019; 15(4):358-368. PMC: 7153547. DOI: 10.1080/15592294.2019.1668739. View

Krause C, Grohs M, El Gammal A, Wolter S, Lehnert H, Mann O . Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis. Endocr Connect. 2018; 7(12):1448-1456. PMC: 6300861. DOI: 10.1530/EC-18-0499. View

10.

Gim J, Bang S, Lee Y, Lee Y, Yim S, Jung Y . Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS One. 2021; 16(8):e0255822. PMC: 8345824. DOI: 10.1371/journal.pone.0255822. View

11.

Ekstedt M, Franzen L, Mathiesen U, Thorelius L, Holmqvist M, Bodemar G . Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865-73. DOI: 10.1002/hep.21327. View

12.

Kim G, Lee H, Choe J, Kim M, Lee M, Chang H . Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017; . DOI: 10.1016/j.jhep.2017.09.012. View

13.

Lyall M, Thomson J, Cartier J, Ottaviano R, Kendall T, Meehan R . Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. Epigenetics. 2019; 15(1-2):61-71. PMC: 6961686. DOI: 10.1080/15592294.2019.1649527. View

14.

Sinha R, Singh B, Yen P . Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab. 2014; 25(10):538-45. DOI: 10.1016/j.tem.2014.07.001. View

15.

Jin Z, Liu Y . DNA methylation in human diseases. Genes Dis. 2018; 5(1):1-8. PMC: 6147084. DOI: 10.1016/j.gendis.2018.01.002. View

16.

Duseja A, Chalasani N . Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int. 2015; 7 Suppl 2:755-64. DOI: 10.1007/s12072-013-9480-x. View

17.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

18.

Johnson R, Vanderlinden L, Dong F, Carry P, Seifert J, Waugh K . Longitudinal DNA methylation differences precede type 1 diabetes. Sci Rep. 2020; 10(1):3721. PMC: 7048736. DOI: 10.1038/s41598-020-60758-0. View

19.

Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward C, Jimenez L, Melnyk S . Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. Toxicol Sci. 2019; 170(2):273-282. PMC: 6934890. DOI: 10.1093/toxsci/kfz110. View

20.

Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View